uniQure Heads Into Earnings With Shorts Rebuilding and Borrow Costs Rising

QURE enters its November 9 earnings date with a quietly shifting short position, analyst opinion divided sharply along a clinical inflection point, and retail attention running at a multi-month high.

Short interest has crept back up after a material retreat. It ended the week at 14.2% of the free float, up roughly 1.9% on the week and 3% on the day, after falling from above 15% in late September and early October. The month-long trend is still lower: short interest peaked near 16% in late September and has pulled back by about 5.6% over that stretch. What's notable this week is the reversal of that decline, with shorts adding back positions in the two sessions before the print. The borrow cost has risen sharply at the same time: the cost to borrow climbed 45% on the week to 0.62%, and has more than tripled over the past month from a low near 0.19% in early October. That's still a low absolute rate, and availability is loose at 970% of short interest, meaning the lending pool holds roughly ten shares for every one currently borrowed. There is no squeeze pressure here. What the rising borrow cost does signal is renewed demand for the short. Options confirm the same read: the put/call ratio edged up to 0.26, running slightly above its 20-day average of 0.24, a modest bias toward hedging but nowhere near the defensive extremes the stock has seen. The 52-week PCR high sits at 0.68, so current positioning is decidedly call-heavy by historical standards.

The Street is split, and the recent moves tell a stark story. Barclays downgraded QURE on October 5 from Overweight to Equal-Weight, cutting the target from $60 to $28, a move that signalled a meaningful step down in conviction on near-term execution. Goldman Sachs cut its target from $46 to $31 on September 30 while holding its Neutral rating. RBC trimmed from $65 to $48 while maintaining Outperform. Against that, UBS assumed coverage on October 15 with a Buy and a $48 target, the most constructive fresh initiation in months. The mean target across the Street is $53.88, more than double the current price of $23.87, suggesting the consensus still prices in a material recovery. But that gap reflects the binary nature of the story rather than a straightforward value call. The bull case rests on FDA acceptance of three-year AMT-130 Phase I/II data for a BLA filing path, removing the sham-surgery hurdle and opening a credible commercialisation route for the Huntington's program, with a potential US launch targeting around 6,000 patients at pricing comparable to other hospital-administered gene therapies. The bear case centres on trial failure risk, competition from Pfizer, Ionis and Wave Life Sciences, and ongoing execution uncertainty across multiple programs.

Institutional ownership adds an interesting layer. Avoro Capital is the largest holder with just under 10% of shares, and has been building: its 13G shows an increase from 6.6% to 9.87% as of February. JPMorgan added over 1.9 million shares in the quarter ending September 30, pushing its stake to 6.8% of shares. RTW Investments filed a 13G in August showing a rise from 4.1% to 5.7%. These are all passive, non-activist filings, with no 13D on the register. The disclosure caveat applies: positions are as last filed and holders below 5% can exit without further notice. Aberdeen and Two Sigma have been trimming. The insider register is quieter: the CMO received an award grant on October 30, and the most recent open-market activity from the CEO involved plan-driven sales in July when the stock was trading above $44. With the stock now closer to $24, those sales look prescient in hindsight, though the 10b5-1 plan designation removes the informational content.

Retail attention is running well above its recent norm. The ORTEX alt data layer flags that Wikipedia views for QURE have spiked to a z-score of 3.3 against the company's own 90-day history, the highest attention reading captured in the dataset as of October 22. That is a pure attention signal: it tracks eyeballs, not revenue, and no measured lead exists that links it to any reported financial figure. What it reflects is that the FDA regulatory news in October put uniQure on a broader readership radar. In recent earnings history, the July 31 print produced a 4.4% one-day gain and a 10% five-day move; the Q2 2026 print on July 29 produced 15.1% on the day and 20.7% over five days. Both were positive surprises, and both came off a lower base. The November 9 print arrives with the stock well off those July highs following the September clinical setback that drove the Barclays downgrade.

The next session's attention will be on whether AMT-130 data framing in the results commentary reinforces the FDA's BLA acceptance signal, or whether updated clinical numbers introduce new uncertainty around efficacy durability.